Skip to main content
SpringerLink
Log in

The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions

  • Review Article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

It has recently been recognized that many patients with congestive heart failure (CHF) are anemic. The anemia is very often associated with chronic kidney disease (CKD). The more severe the anemia the more severe the CHF, with higher mortality, morbidity, and hospitalization rate. The only way to prove that the anemia is itself a causative factor in the progression of both the CKD and the CHF is to correct it. In this paper we review the results of published papers and some preliminary reports about correction of this anemia in CHF. These studies frequently showed that erythropoietic stimulating agents (ESA) with oral or IV iron often resulted in improvement in left ventricular systolic and diastolic function, dilation, and hypertrophy, stabilization or improvement in renal function, reduced hospitalizations, diuretic dose, mitral regurgitation, pulmonary artery pressure, plasma volume, heart rate, serum brain natriuretic peptide levels, and the inflammatory markers C reactive protein and Interleukin 6, and an improvement in New York Heart Association class, exercise capacity, oxygen utilization during exercise, sleep apnea, caloric intake, depression, and quality of life. The activity of endothelial progenitor cells was also increased. Iron deficiency may also play an important role in the anemia, because significant improvement of cardiac, renal, and functional status in these anemic CKD–CHF has been seen after treatment with IV iron alone. Clearly more work is needed to clarify the relationship between anemia, CKD and CHF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hunt SA, Abraham WT, Chin MC, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article. J Am Coll Cardiol. 2005;46:1116–43.

    Article  Google Scholar 

  2. Silverberg DS, Wexler D, Iaina A, Schwartz D. The interaction between heart failure and other heart disease and anemia. Semin Nephrol. 2006;26:296–306.

    Article  PubMed  Google Scholar 

  3. Lindenfeld JA. Prevalence of anemia and the effects on mortality in patients with heart failure. Am Heart J. 2005;149:340–91.

    Article  Google Scholar 

  4. Tang YD, Katz SD. The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes. Heart Fail Rev. 2008 Feb (ahead of print).

  5. Anand IS, Kuskowski MA, Rector TS, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val–Heft. Circulation. 2005;112:1121–7.

    Article  CAS  PubMed  Google Scholar 

  6. Komajda M, Anker SD, Charlesworth A, et al. The impact of new onset anemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J. 2006;27:1441–6.

    Article  Google Scholar 

  7. Tang WHW, Tong W, Jain A, Francis GS, Harris CM, Young JB. Evaluation and long-term prognosis of new-onset, transient and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol. 2008;51:569–76.

    Article  PubMed  Google Scholar 

  8. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function, functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737–44.

    Article  CAS  PubMed  Google Scholar 

  9. Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anemia in diabetics and non diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant. 2003;18:141–6.

    Article  CAS  PubMed  Google Scholar 

  10. Vaisman N, Silverberg DS, Wexler D, et al. Correction of anemia in patients with congestive heart failure increases resting energy expenditure. Clin Nutr. 2004;23:355–61.

    Article  CAS  PubMed  Google Scholar 

  11. Silverberg DS, Wexler D, Blum M, et al. Effects of treatment with EPO beta on outcomes in patients with anaemia and chronic renal failure. Kidney Blood Press Res. 2005;28:41–7.

    Article  CAS  PubMed  Google Scholar 

  12. George J, Goldstein E, Abashidze A, et al. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc Res. 2005;68:299–306.

    Article  CAS  PubMed  Google Scholar 

  13. Zilberman M, Silverberg DS, Bits I, et al. Improvement of anemia with erythropoietin and intravenous iron reduces sleep related breathing disorders (SRBD) and improves daytime sleepiness in anemic congestive heart failure (CHF) patients. Am Heart J. 2007;154:870–6.

    Article  CAS  PubMed  Google Scholar 

  14. Silverberg DS, Sheps D, Wexler D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:1775–80.

    Article  CAS  PubMed  Google Scholar 

  15. Comin-Colet J, Ruiz-Ruiz V, Ortega A et al. Influence of neurohormonal activation and outcome of correction of mild anemia with intravenous iron and erythropoietin in patients with chronic heart failure and cardio-renal-anemia syndrome. Eur Heart J. 2006;28:Abstract 269.

  16. Cosyns B, Lancellotti P, Velez-Roa S, Mantia M, Pierard LA. Does treatment with erythropoietin improve left ventricular systolic performance and mitral regurgitation in anemic patients with chronic heart failure and renal insufficiency? Eur Heart J. 2006;27: Abstract 339.

  17. Pappas KD, Gouva CD, Katopodis KP, et al. Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance. Cardiovasc Drugs Ther. 2007;22:37–44.

    Article  PubMed  Google Scholar 

  18. Mancini DM, Katz SD, Lang C, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107:294–9.

    Article  CAS  PubMed  Google Scholar 

  19. Parissis JT, Kourea K, Panou F et al. Effects of darbepoetin α on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J. 2008;155:751.e1–7.

    Article  PubMed  Google Scholar 

  20. Kourea K, Parissis JT, Farmakis D et al. Effects of darbepoetin-alfa on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin 10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure. Atherosclerosis. 2008;199:215–21.

    Article  CAS  PubMed  Google Scholar 

  21. Kourea K, Parissis JT, Farmakis D, et al. Effects of darbepoetin-alfa on quality of life and emotional stress in anemic patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil. 2008;15:365–9.

    Article  PubMed  Google Scholar 

  22. Palazzuoli A, Silverberg DS, Iovine F, et al. Erythropoietin improves anemia, exercise tolerance, and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J. 2006;152: 1096e9–15.

    Article  Google Scholar 

  23. Palazzuoli A, Silverberg DS, Iovine F et al. Effects of beta Erythropoietin on left ventricular remodeling, systolic function and beta-type Natriuretic peptide levels in patients with cardio-renal anemia syndrome. Am Heart J. 2007;154:645e9–15.

    Article  Google Scholar 

  24. Ghali JK, Anand IS, Abraham WT et al. The effects of increased hemoglobin concentration on clinical outcomes in patients with symptomatic heart failure and anemia: results from STAMINA–Heft. Am Heart Assoc meeting Chicago. Nov 2006: Abstract 2736.

  25. Ghali J, Anand I, Abraham WT, et al. Randomized double blind trial of darbepoetin alpha treatment in patients with symptomatic heart failure and anemia. Circulation. 2008;117:526–35.

    Article  CAS  PubMed  Google Scholar 

  26. Van Veldhuisen DJ, Dickstein K, Cohen-Solal A, et al. Randomized double blind placebo-controlled trial to evaluate the effect of two dosing regimens of darbepoetin alpha in patients with heart failure and anaemia. Eur Heart J. 2007;28:2208–16.

    Article  PubMed  Google Scholar 

  27. Ponikowski P, Anker SD, Szachniewicz J, et al. Effect of darbepoetin alpha on exercise tolerance in anemic patients with symptomatic chronic heart failure. J Am Coll Cardiol. 2007;49:753–62.

    Article  CAS  PubMed  Google Scholar 

  28. Abraham WT, Klapholz M, Anand I et al. The effect of darbepoetin alfa treatment on clinical outcomes on anemic patients with symptomatic heart failure: a preplanned pooled analysis of two randomized, double-blind, placebo-controlled trials. Eur J Heart Fail. 2006; 5 Suppl: Abstract 548.

  29. Bennett CL, Silver SM, Djulbegovic BT, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914–24.

    Article  CAS  PubMed  Google Scholar 

  30. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American society of hematology/American society of clinical oncology clinical practice guideline update. Blood. 2008;111:25–41.

    Article  CAS  PubMed  Google Scholar 

  31. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;39:584–90.

    Article  Google Scholar 

  32. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–98.

    Article  CAS  PubMed  Google Scholar 

  33. Drueke TB, Locatelli F, Clyne N, et al. Normalization of haemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–84.

    Article  CAS  PubMed  Google Scholar 

  34. Strippoli GFM, Tognoni G, Navaneethan SK, Nicolluci A, Craig JC. Haemoglobin targets: we were wrong, time to move on. Lancet. 2007;369:346–50.

    Article  PubMed  Google Scholar 

  35. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target hemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369:381–8.

    Article  CAS  PubMed  Google Scholar 

  36. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol. 2008;141:14–31.

    Article  CAS  PubMed  Google Scholar 

  37. Bolger AP, Bartlett FP, Penston HS, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol. 2006;48:1225–7.

    Article  CAS  PubMed  Google Scholar 

  38. Toblli J, Lombrana A, Duarte P, Di Gennaro F. Intravenous iron reduces NT- pro-BNP in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50:1657–65.

    Article  CAS  PubMed  Google Scholar 

  39. Usmanov RI, Zueva EB, Silverberg DS, Shaked M. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic renal insufficiency. J Nephrol. 2008;21:236–42.

    CAS  PubMed  Google Scholar 

  40. Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency. J Am Coll Cardiol. 2008;51:103–12.

    Article  CAS  PubMed  Google Scholar 

  41. Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J. 2005;26:2232–7.

    Article  CAS  PubMed  Google Scholar 

  42. Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol. 2006;48:2485–9.

    Article  PubMed  Google Scholar 

  43. Anand IS. Heart Failure and anemia: mechanisms and pathophysiology. Heart Fail Rev. 2008 (ahead of print).

  44. Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis patients’ response to IV Iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol. 2007;8:975–84.

    Article  Google Scholar 

  45. Kapoian T, O’Mara NB, Singh AK, et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008;19:372–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Gotloib L, Silverberg DS, Fudin R, Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol. 2006;19:161–7.

    CAS  PubMed  Google Scholar 

  47. Mircescu G, Garneata L, Capusa C, Ursea N. Intravenous iron supplementation for the treatment of anemia in predialyzed chronic renal failure patients. Nephrol Dial Transplant. 2006;21:120–4.

    Article  CAS  PubMed  Google Scholar 

  48. Weiss G, Gordeuk VR. Benefits and risks of iron therapy for chronic anemias. Eur J Clin Invest. 2005;35 Suppl 3:36–45.

    Article  CAS  PubMed  Google Scholar 

  49. Sengolge G, Horl WH, Sunder-Plassmann GS. Intravenous iron therapy: well tolerated but not harmless. Eur J Clin Invest. 2005;35 Suppl 3:46–51.

    Article  CAS  PubMed  Google Scholar 

  50. Kang JO, Jones C, Brothwell B. Toxicity associated with iron overload found in hemochromatosis: possible mechanism in a rat model. Clin Lab Sci. 1998;11:350–4.

    CAS  PubMed  Google Scholar 

  51. Maruyama Y, Nakayama M, Yoshimura K, et al. Effect of repeated intravenous iron administration in hemodialysis patients on serum 8-hydroxy-2′-deoxyguanosine levels. Nephrol Dial Transplant. 2007;22:1407–12.

    Article  CAS  PubMed  Google Scholar 

  52. Yoshimura K, Nakano H, Yokoyama K, Nakayama M. High iron storage levels are associated with increased DNA oxidative injury in patients on regular hemodialysis. Clin Exp Nephrol. 2005;9:158–63.

    Article  CAS  PubMed  Google Scholar 

  53. Nakamura T, Keep RF, Hua Y, Nagao S, Hoff JT, Xi G. Iron-induced oxidative brain injury after experimental intracerebral hemorrhage. Acta Neurochir Suppl. 2006;96:194–8.

    Article  CAS  PubMed  Google Scholar 

  54. Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol. 2004;15:1623–32.

    Article  CAS  PubMed  Google Scholar 

  55. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16:3070–80.

    Article  CAS  PubMed  Google Scholar 

  56. Hoen B, Paul-Dauphin M, Hestin D, Krssler M. EPIBACTIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol. 1998;9:869–76.

    CAS  PubMed  Google Scholar 

  57. Grune T, Sommerburg O, Siems WG. Oxidative stress in anemia. Clin Nephrol. 2000;53 Suppl 1: S18–22.

    CAS  PubMed  Google Scholar 

  58. Ludat K, Sommerburg O, Grune T, Siems WG, Riedel E, Hampl H. Oxidation parameters in complete correction of renal anemia. Clin Nephrol. 2000;53 Suppl 1: S30–5.

    CAS  PubMed  Google Scholar 

  59. Pfeffer MA. An ongoing study of anemia correction in chronic kidney disease. N Engl J Med. 2007;356:959–61.

    Article  CAS  PubMed  Google Scholar 

  60. van Veldhuisen DJ, McMurray JJV. Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomized outcome trial. Eur Heart J. 2007;9:110–2.

    Article  Google Scholar 

  61. Singh AK, Fishbane S. The optimal hemoglobin in dialysis patients—a critical review. Semin Dial. 2008;21:1–6.

    Article  PubMed  Google Scholar 

  62. US Food and Drug Administration: information for healthcare professionals erythropoiesis stimulating agents (ESA). FDA Alert. Nov 8 2007. http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE200711HCP.htm

  63. Young JB, Abraham WY, Albert NM, et al. Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE–HF registry). Am J Cardiol. 2008;101:223–30.

    Article  CAS  PubMed  Google Scholar 

  64. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Secular trends in renal dysfunction and outcomes in hospitalized heart failure patients. J Cardiac Fail. 2006;12:257–62.

    Article  Google Scholar 

  65. De Luca L, Mebazaa A, Filippatos G, et al. Overview of emerging pharmacologic agents for acute heart failure syndromes. Eur J Heart Fail. 2008;10:201–13.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, Tel Aviv Medical Center, Weizman 6, 64239, Tel Aviv, Israel

    Donald S. Silverberg, Adrian Iaina & Doron Schwartz

  2. Department of Cardiology and Heart Failure Unit, Tel Aviv Medical Center, Weizman 6, 64239, Tel Aviv, Israel

    Dov Wexler

Authors
  1. Donald S. Silverberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dov Wexler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adrian Iaina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Doron Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Donald S. Silverberg.

About this article

Cite this article

Silverberg, D.S., Wexler, D., Iaina, A. et al. The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions. Clin Exp Nephrol 13, 101–106 (2009). https://doi.org/10.1007/s10157-008-0074-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-008-0074-1

Keywords

Search

Navigation